1. Home
  2. MP vs DVA Comparison

MP vs DVA Comparison

Compare MP & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MP Materials Corp.

MP

MP Materials Corp.

HOLD

Current Price

$68.63

Market Cap

9.0B

ML Signal

HOLD

Logo DaVita Inc.

DVA

DaVita Inc.

HOLD

Current Price

$108.85

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MP
DVA
Founded
2017
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Misc Health and Biotechnology Services
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
8.2B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
MP
DVA
Price
$68.63
$108.85
Analyst Decision
Strong Buy
Hold
Analyst Count
13
4
Target Price
$70.92
$145.00
AVG Volume (30 Days)
8.3M
782.5K
Earning Date
02-19-2026
02-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.63
EPS
N/A
9.76
Revenue
$232,742,000.00
$13,317,965,000.00
Revenue This Year
$34.68
$6.50
Revenue Next Year
$137.40
$2.97
P/E Ratio
N/A
$10.89
Revenue Growth
26.44
5.14
52 Week Low
$18.64
$101.00
52 Week High
$100.25
$179.60

Technical Indicators

Market Signals
Indicator
MP
DVA
Relative Strength Index (RSI) 61.36 43.91
Support Level $61.52 $103.48
Resistance Level $71.69 $106.38
Average True Range (ATR) 4.71 3.31
MACD 0.95 -0.16
Stochastic Oscillator 85.18 53.37

Price Performance

Historical Comparison
MP
DVA

About MP MP Materials Corp.

MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.

About DVA DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

Share on Social Networks: